

CONTACTS:

Ellen Semple
BioAdvance
215-966-6207

Bill Berry
Berry & Company
212-253-8881

John Gill and Steven Nichtberger, M.D., Join BioAdvance Board of Directors

Philadelphia, PA, February 8, 2008 – BioAdvance, the Biotechnology Greenhouse of Southeastern Pennsylvania, announced today the appointment of John M. Gill and Steven Nichtberger, M.D., to the organization’s board of directors.

Both Mr. Gill and Dr. Nichtberger have distinguished careers in the biopharmaceutical industry including their current roles as founders and chief executives of innovative, emerging life sciences companies. Mr. Gill is co-founder, president and CEO of Tetralogic Pharmaceuticals, a Malvern-based firm focused on new drugs to treat cancer by modulating the apoptosis (programmed cell death) pathway. Previously he held senior management positions in operations and finance with SmithKline Beecham Corporation and 3 Dimensional Pharmaceuticals. He also served as a founding member and partner in SR One, Limited, SmithKline Beecham’s life sciences venture capital fund.

Dr. Nichtberger is president and CEO of Tengion, the suburban Philadelphia firm focused on regenerative medicine and the use of a patient’s own cells to develop new organs and tissues. Tengion recently initiated the third Phase 2 clinical trial of its Neo-Bladder™, the company’s first investigational product. Dr. Nichtberger is a former senior executive at Merck where he was responsible for leadership of global marketing and new product planning and was a core participant in many corporate licensing, divestiture and product acquisition deals. Dr. Nichtberger is a board certified internist and cardiologist.

“I’m pleased to welcome John and Steven to the BioAdvance Board of Directors,” said Russel Kaufman, M.D., President and CEO of The Wistar Institute and Chairman of the BioAdvance Board of Directors. “They represent the wealth of life sciences expertise that is one of the Philadelphia area’s richest resources. With their help, BioAdvance will grow this resource to its full potential.”

BioAdvance has invested more than \$11.5 million in 21 early stage life sciences companies and nine academic projects. BioAdvance is continuing to identify and review promising life science companies for investment. Life science companies interested in being considered for investment

by BioAdvance can get application information at www.bioadvance.com. Applications received before March 8, 2008 qualify to be considered for the current funding review cycle.

“John and Steve are outstanding advocates for the region,” said Barbara S. Schilberg, BioAdvance CEO and managing director. “They also bring significant entrepreneurial and industry perspectives that will help BioAdvance in its mission of making this region the leading place to build successful life sciences companies.”

About BioAdvance

BioAdvance is one of the nation’s leading investors providing pre-seed and seed stage funding to emerging life sciences companies. Established in 2002 with \$33.8 million from the Commonwealth of Pennsylvania’s share of tobacco settlement monies, BioAdvance identifies and invests in promising research and technologies that could lead to important advances in medicine and human health. To date, BioAdvance has invested \$11.5 million in 21 life sciences companies and nine academic projects. Companies in the BioAdvance portfolio are working to develop products to treat serious health problems including Alzheimer’s disease, cancer, diabetes, GI disorders, neurological and respiratory illnesses and have gone on to raise over \$215 million in additional capital. For more information visit www.bioadvance.com